Biologic therapy-Related demyelinating peripheral neuropathy in a child with Juvenile Idiopathic Arthritis

Article Sidebar

PDF HTML
Submitted: July 3, 2018
Published: Jul 19, 2018
DOI: 10.29328/journal.apps.1001008
Keywords:
Juvenile idiopathic arthritis, TNF- inhibitor, Abatacept, Demyelination neuropathy

Main Article Content

Heba A Alqurashi
Department of Neuroscience, Pediatric neurology, King Faisal Specialist Hospital and Research Center, Alfaisal University, Riyadh, Saudi Arabia
Ghada Al-Salmi
Department of Pediatric, Pediatric Rheumatology, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia
Mohammad A Al-Muhaizea
Department of Neuroscience, Pediatric neurology, King Faisal Specialist Hospital and Research Center, Alfaisal University, Riyadh, Saudi Arabia
Sulaiman M Al-Mayouf
Department of Pediatric, Pediatric Rheumatology, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia

Abstract

Demyelinating peripheral neuropathy has been described in association with tumor necrosis factor (TNF) inhibitors. It is rarely developed after treatment discontinuation. We present the case of a child with juvenile idiopathic arthritis who developed peripheral neuropathy few months after TNF inhibitor withdrawal with clinical worsening of the neurological sequelae while undergoing treatment with abatacept.

Article Details

Alqurashi, H. A., Al-Salmi, G., Al-Muhaizea, M. A., & Al-Mayouf, S. M. (2018). Biologic therapy-Related demyelinating peripheral neuropathy in a child with Juvenile Idiopathic Arthritis. Archives of Pharmacy and Pharmaceutical Sciences, 2(1), 020–022. https://doi.org/10.29328/journal.apps.1001008
Case Reports

Copyright (c) 2018 Alqurashi HA, et al.

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Furst D, Keystone E, Braun J, Breedveld F, Burmester G, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010. Ann Rheum Dis. 2011; 70: i2-36. Ref.: https://tinyurl.com/ydhu4qoy

Davies R, Carrasco R, Foster H, Balidam E, Chieng S, et al. Treatment prescribing patterns in patients with juvenile idiopathic arthritis (JIA): Analysis from the UK Childhood Arthritis Prospective (CAPS). Semin Arthritis Rheum. 2016; 46: 190-195. Ref.: https://tinyurl.com/yayoxrsp

Horneff G. Safety of biologic therapies for the treatment of juvenile idiopathic arthritis. Expert Opin Drug Saf. 2015; 14: 1111-1126. Ref.: https://tinyurl.com/y7s7dncp

Hashkes P, Uziel Y, Laxer R. The safety profile of biologic therapies for juvenile idiopathic arthritis. Nat Rev Rheumatol. 2010; 6: 561- 571. Ref.: https://tinyurl.com/y7ov3ckz

Al-Mayouf S, Alenazi A, ALJasser H. Biologic agents therapy for Saudi children with rheumatic diseases: indications and safety. Int J Rheum Dis. 2016; 19: 600- 605. Ref.: https://tinyurl.com/ydgjmw76

Yagita M, Hamano T, Hatachi S, Fujita M. Peripheral neuropathies during biologic therapies. Mod Rheumatol. 2016; 26: 288-293.

Seror R, Richez C, Sordet C, Rist S, Gossec L, et al. Pattern of demyelination occurring during anti-TNF- therapy: a French national survey. Rheumatology (Oxford). 2013; 52: 868-874. Ref.: https://tinyurl.com/yc8ayp7k

Ramos-Casals M, Roberto-Perez-Alvarez, Diaz-Lagares C, Cuadrado M, Khamashta M. Autoimmune diseases induced by biological agents: a double-edged sword? Autoimmun Rev. 2010; 9: 188-193. Ref.: https://tinyurl.com/y95jxhna

Perez-Alvarez R, Pérez-De-Lis M, Ramos-Casals M. Biologics-induced autoimmune diseases. Curr Opin Rheumatol. 2013; 25: 56-64. Ref.: https://tinyurl.com/yd7hpn5p

Alvarez-Lario B, Prieto-Tejedo R, Colazo-Burlato M, Macarron-Vicente J. Severe Guillain-Barre syndrome in a patient receiving anti-TNF therapy. Consequence or coincidence. A case-based review. Clin Rheumatol. 2013; 32: 1407-1412. Ref.: https://tinyurl.com/ybf9zbmt

Herrero-Beaumont G, Martínez Calatrava M, Castañeda S. Abatacept mechanism of action: concordance with its clinical profile. Reumatol Clín. 2012; 8: 78-83.